PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

ClinicalTrials.gov ID: NCT05096481

Public ClinicalTrials.gov record NCT05096481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD

Study identification

NCT ID: NCT05096481
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Nationwide Children's Hospital; Other
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 3 Years to 39 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 18, 2024 (Actual)
Primary completion: Jun 15, 2028 (Estimated)
Completion: Jun 15, 2030 (Estimated)
Last update posted: Aug 24, 2026

2024 – 2030

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
Children's Hospital Colorado	Aurora	Colorado	80045	Recruiting
Children's National Medical Center	Washington D.C.	District of Columbia	20010	Recruiting
Nicklaus Children's Hospital	Miami	Florida	33155	Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	60611	Not yet recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Not yet recruiting
C.S. Mott Children's Hospital	Ann Arbor	Michigan	48109	Recruiting
St. Louis Children's Hospital	St Louis	Missouri	63110	Recruiting
Duke Cancer Center	Durham	North Carolina	27710	Recruiting
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	Recruiting
Nationwide Children's Hospital	Columbus	Ohio	43205	Recruiting
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	Not yet recruiting
Texas Children's Hospital	Houston	Texas	77030	Recruiting
Seattle Children's Hospital	Seattle	Washington	98105	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05096481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05096481 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →